PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine

Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment

(2017) Qiaohong Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12

(2017) S. De Koker et al.   Scientific Reports

Transfer of Allogeneic CD4 + T Cells Rescues CD8 + T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication

(2017) Ainhoa Arina et al.   Cancer Immunology Research

Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine

(2017) Chun-yan Wang et al.   Cancer Medicine

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy

(2016) Guru Sonpavde et al.   BJU INTERNATIONAL

Immunotherapy for prostate cancer: False promises or true hope?

(2016) Brian T. Rekoske et al.   CANCER

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer

(2016) Federica Cappuccini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

(2016) Marlon C. Rebelatto et al.   Diagnostic Pathology

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment

(2016) Mariko Hirai et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

(2016) Madison Black et al.   Oncotarget

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

(2016) R. F. Sweis et al.   Cancer Immunology Research

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction

(2016) Djoke Hendriks et al.   OncoImmunology

IL-4–Secreting Secondary T Follicular Helper (Tfh) Cells Arise from Memory T Cells, Not Persisting Tfh Cells, through a B Cell–Dependent Mechanism

(2015) Keke C. Fairfax et al.   JOURNAL OF IMMUNOLOGY

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

(2015) Kevin C. Soares et al.   JOURNAL OF IMMUNOTHERAPY

Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery

(2015) AGNIESZKA KOLACINSKA et al.   Oncology Letters

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer

(2015) Yi Qing et al.   Drug Design Development and Therapy

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer

(2015) Tao Qin et al.   Oncotarget

Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors

(2015) Margarida Ferreira-Teixeira et al.   Oncotarget

Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine

(2015) Yong-tong Zhu et al.   Stem Cell Research & Therapy

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

(2015) O. A. Ali et al.   Cancer Immunology Research

Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer

(2014) Rani Ojha et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors

(2014) J. Fu et al.   CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Interleukin-10 Receptor Signaling in Innate Immune Cells Regulates Mucosal Immune Tolerance and Anti-Inflammatory Macrophage Function

(2014) Dror S. Shouval et al.   IMMUNITY

USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity

(2014) Bangxing Hong et al.   Molecular Cancer

The granulocyte macrophage–colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer

(2014) Yong-tong Zhu et al.   Stem Cell Research

Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells

(2012) F. M. Hofman et al.   Anti-Cancer Agents in Medicinal Chemistry

Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer

(2011) Qiushan He et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer

(2010) Weihua Yin et al.   VACCINE

Tunable Chemokine Production by Antigen Presenting Dendritic Cells in Response to Changes in Regulatory T Cell Frequency in Mouse Reactive Lymph Nodes

(2009) Valentina Dal Secco et al.   PLoS One